Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Reiterates Buy on Dicerna Pharma (DRNA) Following 4Q - PT to $19
March 11, 2016 9:38 AM ESTJefferies maintained a Buy rating on Dicerna Pharmaceuticals (NASDAQ: DRNA), and cut the price target to $19.00 (from $25.00), following the company's 4Q. DRNA reported a Narrower 4Q15 net loss of $15.7M, compared to Jefferies' net loss estimate of $18.1M.
Analyst Eun Yang... More
Dicerna Pharma (DRNA) Tops Q4 EPS by 8c
March 10, 2016 4:10 PM ESTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.76), $0.08 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... More